562 related articles for article (PubMed ID: 33609072)
1. Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial.
Tromp J; Ponikowski P; Salsali A; Angermann CE; Biegus J; Blatchford J; Collins SP; Ferreira JP; Grauer C; Kosiborod M; Nassif ME; Psotka MA; Brueckmann M; Teerlink JR; Voors AA
Eur J Heart Fail; 2021 May; 23(5):826-834. PubMed ID: 33609072
[TBL] [Abstract][Full Text] [Related]
2. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
Voors AA; Angermann CE; Teerlink JR; Collins SP; Kosiborod M; Biegus J; Ferreira JP; Nassif ME; Psotka MA; Tromp J; Borleffs CJW; Ma C; Comin-Colet J; Fu M; Janssens SP; Kiss RG; Mentz RJ; Sakata Y; Schirmer H; Schou M; Schulze PC; Spinarova L; Volterrani M; Wranicz JK; Zeymer U; Zieroth S; Brueckmann M; Blatchford JP; Salsali A; Ponikowski P
Nat Med; 2022 Mar; 28(3):568-574. PubMed ID: 35228754
[TBL] [Abstract][Full Text] [Related]
3. Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trial.
Tromp J; Kosiborod MN; Angermann CE; Collins SP; Teerlink JR; Ponikowski P; Biegus J; Ferreira JP; Nassif ME; Psotka MA; Brueckmann M; Blatchford JP; Steubl D; Voors AA
Eur J Heart Fail; 2024 Apr; 26(4):963-970. PubMed ID: 38572654
[TBL] [Abstract][Full Text] [Related]
4. Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial.
Kosiborod MN; Angermann CE; Collins SP; Teerlink JR; Ponikowski P; Biegus J; Comin-Colet J; Ferreira JP; Mentz RJ; Nassif ME; Psotka MA; Tromp J; Brueckmann M; Blatchford JP; Salsali A; Voors AA
Circulation; 2022 Jul; 146(4):279-288. PubMed ID: 35377706
[TBL] [Abstract][Full Text] [Related]
5. Early treatment with a sodium-glucose co-transporter 2 inhibitor in high-risk patients with acute heart failure: Rationale for and design of the EMPA-AHF trial.
Horiuchi Y; Matsue Y; Nogi K; Onitsuka K; Okumura T; Hoshino M; Shibata T; Nitta D; Yoshida K; Sato S; Damman K; Voors AA; Kitai T
Am Heart J; 2023 Mar; 257():85-92. PubMed ID: 36503007
[TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE.
Ferreira JP; Blatchford JP; Teerlink JR; Kosiborod MN; Angermann CE; Biegus J; Collins SP; Tromp J; Nassif ME; Psotka MA; Comin-Colet J; Mentz RJ; Brueckmann M; Nordaby M; Ponikowski P; Voors AA
Eur J Heart Fail; 2023 Oct; 25(10):1797-1805. PubMed ID: 37540060
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).
Damman K; Beusekamp JC; Boorsma EM; Swart HP; Smilde TDJ; Elvan A; van Eck JWM; Heerspink HJL; Voors AA
Eur J Heart Fail; 2020 Apr; 22(4):713-722. PubMed ID: 31912605
[TBL] [Abstract][Full Text] [Related]
8. Similarities and distinctions between acetazolamide and sodium-glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE.
Packer M; Butler J
Eur J Heart Fail; 2023 Sep; 25(9):1537-1543. PubMed ID: 37403655
[TBL] [Abstract][Full Text] [Related]
9. The win ratio method in heart failure trials: lessons learnt from EMPULSE.
Pocock SJ; Ferreira JP; Collier TJ; Angermann CE; Biegus J; Collins SP; Kosiborod M; Nassif ME; Ponikowski P; Psotka MA; Teerlink JR; Tromp J; Gregson J; Blatchford JP; Zeller C; Voors AA
Eur J Heart Fail; 2023 May; 25(5):632-641. PubMed ID: 37038330
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.
Abraham WT; Ponikowski P; Brueckmann M; Zeller C; Macesic H; Peil B; Brun M; Ustyugova A; Jamal W; Salsali A; Lindenfeld J; Anker SD;
Eur J Heart Fail; 2019 Jul; 21(7):932-942. PubMed ID: 31218819
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
[TBL] [Abstract][Full Text] [Related]
12. Use of sodium glucose co-transporter 2 inhibitors in acute heart failure: a practical guidance.
Ferreira JP; Pimenta J; Moura B; Aguiar C; Franco F
ESC Heart Fail; 2022 Dec; 9(6):4344-4347. PubMed ID: 36004699
[TBL] [Abstract][Full Text] [Related]
13. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial.
Biegus J; Voors AA; Collins SP; Kosiborod MN; Teerlink JR; Angermann CE; Tromp J; Ferreira JP; Nassif ME; Psotka MA; Brueckmann M; Salsali A; Blatchford JP; Ponikowski P
Eur Heart J; 2023 Jan; 44(1):41-50. PubMed ID: 36254693
[TBL] [Abstract][Full Text] [Related]
14. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
Abraham WT; Lindenfeld J; Ponikowski P; Agostoni P; Butler J; Desai AS; Filippatos G; Gniot J; Fu M; Gullestad L; Howlett JG; Nicholls SJ; Redon J; Schenkenberger I; Silva-Cardoso J; Störk S; Krzysztof Wranicz J; Savarese G; Brueckmann M; Jamal W; Nordaby M; Peil B; Ritter I; Ustyugova A; Zeller C; Salsali A; Anker SD
Eur Heart J; 2021 Feb; 42(6):700-710. PubMed ID: 33351892
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
Packer M; Anker SD; Butler J; Filippatos G; Ferreira JP; Pocock SJ; Sattar N; Brueckmann M; Jamal W; Cotton D; Iwata T; Zannad F;
J Am Coll Cardiol; 2021 Mar; 77(11):1381-1392. PubMed ID: 33736819
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
Packer M; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Anker SD; Zannad F;
Eur J Heart Fail; 2019 Oct; 21(10):1270-1278. PubMed ID: 31584231
[TBL] [Abstract][Full Text] [Related]
17. Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial.
Voors AA; Damman K; Teerlink JR; Angermann CE; Collins SP; Kosiborod M; Biegus J; Ferreira JP; Nassif ME; Psotka MA; Tromp J; Brueckmann M; Blatchford JP; Salsali A; Ponikowski P;
Eur J Heart Fail; 2022 Oct; 24(10):1844-1852. PubMed ID: 36066557
[TBL] [Abstract][Full Text] [Related]
18. Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial.
Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Fosbøl EL; Bruun NE; Brønd JC; Forman JL; Videbæk L; Møller JE; Schou M
Am Heart J; 2020 Oct; 228():47-56. PubMed ID: 32798787
[TBL] [Abstract][Full Text] [Related]
19. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
Santos-Gallego CG; Garcia-Ropero A; Mancini D; Pinney SP; Contreras JP; Fergus I; Abascal V; Moreno P; Atallah-Lajam F; Tamler R; Lala A; Sanz J; Fuster V; Badimon JJ
Cardiovasc Drugs Ther; 2019 Feb; 33(1):87-95. PubMed ID: 30675708
[TBL] [Abstract][Full Text] [Related]
20. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
Jensen J; Omar M; Kistorp C; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Malik ME; Fosbøl EL; Bruun NE; Forman JL; Jensen LT; Møller JE; Schou M
Lancet Diabetes Endocrinol; 2021 Feb; 9(2):106-116. PubMed ID: 33357505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
